Pharmaceutical Investing Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges
Juggernaut Announces Strategic Investment by Crescat Capital Funds for 28.95% Ownership - Dr. Quinton Hennigh Technical Advisor
